Autosomal dominant polycystic kidney disease (NICE TA358)
Tolvaptan is recommended as an option for treating autosomal dominant polycystic kidney disease in adults to slow the progression of cyst development and renal insufficiency only if:
- they have chronic kidney disease stage 2 or 3 at the start of treatment
- there is evidence of rapidly progressing disease and
- the company provides it with the discount agreed in the patient access scheme.
NHS England is the commissioner of dialysis and kidney transplants, hyponatraemia and other endocrine uses.